Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03093116	TitleA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	Phase Phase 1, Phase 2	Date Added 2017-03-28	Location California, United States Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Australia Belgium Canada China Denmark France Germany Hong Kong Hungary Italy Japan Korea, Republic of Netherlands Poland Singapore Spain Taiwan United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Oral repotrectinib (TPX-0005)	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05277051	TitleFirst-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors	Phase Phase 1	Date Added 2022-03-14	Location California, United States North Carolina, United States Oklahoma, United States Pennsylvania, United States Texas, United States Utah, United States Australia Canada China France Japan Korea, Republic of Spain United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Dostarlimab, GSK4381562	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04984369	TitleThe Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment	Phase Phase 2	Date Added 2021-07-30	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Cetuximab Injection [Erbitux], HLX208	Tags MSS/ MMRp
NCT ID NCT02465060	TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Phase Phase 2	Date Added 2015-06-08	Location Alabama, United States Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib	Tags MSS/ MMRp
NCT ID NCT02608385	TitleStudy of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors	Phase Phase 1	Date Added 2015-11-18	Location Illinois, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Pembrolizumab	Tags MSS/ MMRp
NCT ID NCT03289962	TitleA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	Phase Phase 1	Date Added 2017-09-21	Location Arizona, United States California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States Belgium Canada Germany Netherlands Spain Sweden United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab, Autogene cevumeran, Tecentriq	Tags MSS/ MMRp
NCT ID NCT04483219	TitleTyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.	Phase Phase 2	Date Added 2020-07-23	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs TKI ± anti-PD-1 antibody	Tags MSS/ MMRp
NCT ID NCT03658785	TitleImmunotherapy for the Treatment of Advanced Solid Tumor	Phase Phase 1	Date Added 2018-09-05	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Aldesleukin, Cyclophosphamide, Fludarabine, TIL	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03096093	TitleInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer	Phase Phase 1, Phase 2	Date Added 2017-03-30	Location United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs ACIT-1	Tags MSS/ MMRp
NCT ID NCT03692429	TitlealloSHRINK – Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells	Phase Phase 1	Date Added 2018-10-02	Location Florida, United States Belgium	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs CYAD-101, FOLFIRI, FOLFOX	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 101 to 110 of 299 entries